Brief: Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
27/02/2026 21:33
Feb 27 (Reuters) - Aardvark Therapeutics Inc AARD.O: AARDVARK THERAPEUTICS ANNOUNCES VOLUNTARY PAUSE OF PHASE 3 HERO TRIAL IN PRADER-WILLI SYNDROME AARDVARK THERAPEUTICS INC - PAUSE DUE TO CARDIAC OBSERVATIONS AT ABOVE TARGET DOSES AARDVARK THERAPEUTICS INC - TOPLINE DATA ANNOUNCEMENT DELAYED, GUIDANCE EXPECTED IN Q2 2026 Source text: ID:nGNX9KXxwy Further company coverage: AARD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aardvark Therapeutics
See all newsBrief: Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., Mba, To Its Board Of Directors
Aardvark Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction
Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Intel, Nvidia, Aardvark